GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Head to head

Shed vs Zappy Health: Pricing, Evidence and What Neither Discloses

We hold captured pricing for Shed only, so a like-for-like price comparison is not possible yet.

Direct answer

On their own pages, read November 20, 2026 or later, Shed lists $239 (“starting as low as”); Zappy Health lists $299 month to month and $259 at its lowest (6-month plan). One of these is a starting, sale or carried figure, so there is no clean like-for-like monthly comparison. On our written v4.1 scoring guide, Shed scores 55/100 (#17 of 22) and Zappy Health scores 73/100 (#5 of 22).

Answer last reviewed:

The short answer

We hold captured pricing for Shed only, so a like-for-like price comparison is not possible yet. Both figures are provider-reported.

Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.

Compare at a maintenance dose, not at signup

The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.

Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.

What neither has told us

Neither Shed nor Zappy Health has named its fulfilling pharmacy or its registration class. That is true of most providers in our dataset (NexLife’s plan pages do name three 503A pharmacies), and it is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.

The comparison that outranks both

Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.

Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.

Shed against Zappy Health, lowest figure we hold by molecule
TirzepatideShed $199Zappy Health — not capturedSemaglutideShed $149Zappy Health — not capturedShedZappy Health
Show this figure as a table
Data table
ItemShedZappy Health
Tirzepatide$199not captured
Semaglutide$149not captured
Hatched bars mean we hold no figure at all for that molecule from that provider. A dashed edge means the figure is provider-reported rather than captured by us, so the bar is only as reliable as the provider’s own published number. A solid bar is a figure we read at the source ourselves.
Same fields, both providers
Same fields, both providers
FieldShedZappy Health
Lowest captured all-in$149/monot verified
Lowest tirzepatide$199/monot verified
Lowest semaglutide$149/monot verified
Records we hold60
Evidence statusProvider-reported Provider-reportedProvider-reported Provider-reported
Fulfilling pharmacy named to usnono
Registration class disclosednono
State availability verifiednono
Cancellation terms capturednot verifiednot verified
Unverified rows are shown rather than dropped. A field omitted for one side is how a comparison picks a winner without appearing to.
Every captured record for Shed and Zappy Health
ProviderProgramFormulationDose coverageMedicationRequired feesAll-in monthlyPrice typeEvidenceCaptured
Shedprepaidcompounded microdosenot recorded$149not verified$149Commitment tierProvider-reported2026-07-06
Shedprepaidcompounded injectablenot recorded$175not verified$175Commitment tierProvider-reported2026-07-06
Shedprepaidcompounded microdosenot recorded$199not verified$199Commitment tierProvider-reported2026-07-06
Shedmonth_to_monthcompounded sublingualnot recorded$199not verified$199RecurringProvider-reported2026-07-06
Shedprepaidcompounded sublingualnot recorded$229not verified$229Commitment tierProvider-reported2026-07-06
Shedprepaidcompounded injectablenot recorded$245not verified$245Commitment tierProvider-reported2026-07-06

Our editorial pick, NexLife, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan (as of November 20, 2026), the same price at every dose with no membership fee. See NexLife’s current plans.

Questions readers actually ask

Is Shed cheaper than Zappy Health?

On their own pages, read November 20, 2026 or later, Shed lists $239 (“starting as low as”); Zappy Health lists $299 month to month and $259 at its lowest (6-month plan). One of these is a starting, sale or carried figure, so there is no clean like-for-like monthly comparison.

Why is one marked verified and the other reported?

On our written v4.1 scoring guide, Shed scores 55/100 (#17 of 22) and Zappy Health scores 73/100 (#5 of 22). The scores come from each program’s own pages and FDA’s warning-letter index, read November 20–21, 2026.

Does either name its pharmacy?

Shed: ‘A licensed pharmacy’; none named. Zappy Health: ‘A LegitScript-verified 503A compounding pharmacy’; none named.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “Shed vs Zappy Health: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/compare/shed-vs-zappy-health/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4